| Primary |
| Hypopituitarism |
27.9% |
| Growth Hormone Deficiency |
25.7% |
| Growth Retardation |
9.3% |
| Body Height Below Normal |
4.3% |
| Asthma |
3.6% |
| Hypertension |
2.9% |
| Prader-willi Syndrome |
2.9% |
| Renal Failure |
2.9% |
| Adrenal Insufficiency |
2.1% |
| Blood Follicle Stimulating Hormone Decreased |
2.1% |
| Blood Luteinising Hormone Decreased |
2.1% |
| Hyperthyroidism |
2.1% |
| Hypothyroidism |
2.1% |
| Blood Thyroid Stimulating Hormone Decreased |
1.4% |
| Cardiovascular Event Prophylaxis |
1.4% |
| Dyslipidaemia |
1.4% |
| Epilepsy |
1.4% |
| Hypogonadism |
1.4% |
| Ocular Hypertension |
1.4% |
| Primary Hypothyroidism |
1.4% |
|
| Medulloblastoma Recurrent |
16.4% |
| Colon Cancer Metastatic |
8.2% |
| Epilepsy |
6.6% |
| Synovial Cyst |
6.6% |
| Neoplasm Recurrence |
4.9% |
| Obsessive-compulsive Disorder |
4.9% |
| Osteochondrosis |
4.9% |
| Pulmonary Arterial Hypertension |
4.9% |
| Systemic Lupus Erythematosus |
4.9% |
| Viral Pharyngitis |
4.9% |
| Acromegaly |
3.3% |
| Adrenocortical Insufficiency Acute |
3.3% |
| Cellulitis |
3.3% |
| Death |
3.3% |
| Gastric Cancer |
3.3% |
| Hamartoma |
3.3% |
| Intermittent Claudication |
3.3% |
| Lymphoma |
3.3% |
| Melanocytic Naevus |
3.3% |
| Metastatic Neoplasm |
3.3% |
|
| Secondary |
| Hypophysectomy |
17.6% |
| Body Height Below Normal |
14.7% |
| Hypopituitarism |
13.2% |
| Gastrooesophageal Reflux Disease |
8.8% |
| Growth Hormone Deficiency |
8.8% |
| Growth Retardation |
7.4% |
| Product Used For Unknown Indication |
4.4% |
| Renal Failure |
4.4% |
| Asthma |
2.9% |
| Mitochondrial Cytopathy |
2.9% |
| Adrenal Insufficiency |
1.5% |
| Blood Follicle Stimulating Hormone Decreased |
1.5% |
| Blood Luteinising Hormone Decreased |
1.5% |
| Blood Thyroid Stimulating Hormone Decreased |
1.5% |
| Foetal Growth Restriction |
1.5% |
| Hypogonadism Male |
1.5% |
| Off Label Use |
1.5% |
| Ovarian Hyperstimulation Syndrome |
1.5% |
| Overweight |
1.5% |
| Primary Hypothyroidism |
1.5% |
|
| Pulmonary Arterial Hypertension |
11.1% |
| Weight Decreased |
11.1% |
| Gait Disturbance |
8.3% |
| Hypertrophic Cardiomyopathy |
8.3% |
| Intermittent Claudication |
8.3% |
| Synovitis |
8.3% |
| Coma |
5.6% |
| Craniopharyngioma |
5.6% |
| Abortion Spontaneous |
2.8% |
| Gastric Cancer |
2.8% |
| Haematocrit Decreased |
2.8% |
| Herpes Zoster |
2.8% |
| Meningioma |
2.8% |
| Muscle Rigidity |
2.8% |
| Musculoskeletal Stiffness |
2.8% |
| Mydriasis |
2.8% |
| Neuroendocrine Tumour |
2.8% |
| Optic Tract Glioma |
2.8% |
| Osteonecrosis |
2.8% |
| Renal Cancer Metastatic |
2.8% |
|
| Concomitant |
| Abnormal Behaviour |
40.0% |
| Headache |
20.0% |
| Pyrexia |
20.0% |
| Renal Failure Chronic |
20.0% |
|
| Off Label Use |
50.0% |
| Gastroenteritis |
25.0% |
| Renal Failure Acute |
25.0% |
|
